Arcutis Biotherapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

ARQT$27.39+4.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

	Year Ended December 31,
	2023	2022	2021
Revenues:
Product revenue, net	$29,186	$3,686	$—
Other revenue	30,420	—	—
Total revenues	59,606	3,686	—
Operating expenses:
Cost of sales	4,987	754	—
Research and development	110,575	182,435	145,558
Selling, general and administrative	185,145	122,124	60,971
Total operating expenses	300,707	305,313	206,529
Loss from operations	(241,101)	(301,627)	(206,529)
Other income (expense):
Other income, net	11,786	5,821	173
Interest expense	(29,712)	(15,652)	—
Loss before income taxes	(259,027)	(311,458)	(206,356)
Provision for income taxes	3,113	—	—
Net loss	$(262,140)	$(311,458)	$(206,356)
Other comprehensive income (loss):
Unrealized income (loss) on marketable securities	1,186	(831)	(253)
Foreign currency translation adjustment	(96)	—	—
Total other comprehensive income (loss)	1,090	(831)	(253)
Comprehensive loss	$(261,050)	$(312,289)	$(206,609)
Per share information:
Net loss per share, basic and diluted	$(3.78)	$(5.66)	$(4.18)
Weighted-average shares used in computing net loss per share, basic and diluted	69,305,487	55,032,265	49,405,575

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.